Anomalous growth hormone response to vasoactive intestinal peptide and peptide histidine methionine in patients with prolactinoma or hypothalamic hyperprolactinemia.
We examined a possible GH-releasing activity of vasoactive intestinal peptide (VIP) and its homologous peptide, peptide histidine methionine (PHM), in 22 patients with hyperprolactinemia (HPRL) who comprised 19 cases of prolactinoma (PRLoma) and 3 cases of hypothalamic HPRL. Each patient underwent iv bolus injections of VIP (100 micrograms) and PHM (100 micrograms) on separate days, and plasma levels of GH and PRL were measured. The plasma GH response to VIP and PHM were considered positive (a paradoxical increase) when an increase over baseline of at least 50% occurred. In agreement with previous reports, the PRL-releasing activity of VIP and PHM in our patients with HPRL were subnormal. Thirteen (59%) patients showed a paradoxical rise in GH after VIP, and 4 (18%) patients did so after PHM. It is to be noted that all the 3 patients with hypothalamic HPRL responded to VIP with a significant rise in GH. 3 of the 4 PHM-responders were also responsive to VIP, which suggests that PHM may have activated VIP receptors in the pituitary of the PHM-responders as a partial agonist of the VIP receptor. The responders and nonresponders to VIP or PHM, respectively, had similar results with respect to the mean age, and the mean basal PRL and GH levels in the plasma. Since these paradoxical GH responses were observed in not only the patients with PRLoma but also those with hypothalamic HPRL, it may be that these anomalous GH responses in HPRL were due to the HPRL itself rather than due to the neoplastic lactotrophs.(ABSTRACT TRUNCATED AT 250 WORDS)
Watanobe
H
H
Third Department of Internal Medicine, Hirosaki University School of Medicine, Aomori, Japan.
Tamura
T
T
Takahashi
K
K
D000293:Adolescent; D000328:Adult; D005260:Female; D013006:Growth Hormone / Q000378:metabolism*; D006801:Humans; D006966:Hyperprolactinemia / Q000188:drug therapy* / Q000503:physiopathology; D007027:Hypothalamic Diseases / Q000188:drug therapy / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D010451:Peptide PHI / Q000494:pharmacology*; D010911:Pituitary Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D015175:Prolactinoma / Q000188:drug therapy* / Q000378:metabolism; D017386:Sequence Homology, Amino Acid; D014660:Vasoactive Intestinal Peptide / Q000494:pharmacology*
D010451:Peptide PHI; D014660:Vasoactive Intestinal Peptide; D013006:Growth Hormone